<i>Bcl-xL</i> as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in <i>BRAF</i> -mutant stage II and III colon cancer

Philip D. Dunne(Queen's University Belfast), Mark Lawler(Queen's University Belfast)
bioRxiv (Cold Spring Harbor Laboratory)
October 23, 2017
10.1101/207639
Cited by 1

Related Papers

<i>Bcl-xL</i> as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in <i>BRAF</i> -mutant stage II and III colon cancer
|Oncotarget|2018|11